Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

This study tests a combination of two drugs — fruquintinib (a targeted therapy) and raltitrexed (a chemotherapy) — in patients with metastatic colorectal cancer that has stopped responding to standard treatments. Colorectal cancer that has spread is hard to treat in later lines of therapy, and this combination aims to offer a new option. **You may be eligible if:** - You are 18 or older - You have confirmed advanced metastatic colorectal cancer (adenocarcinoma type) - Your cancer has progressed after receiving at least the standard therapies including fluorouracil, oxaliplatin, and irinotecan - Your overall health is reasonably good **You may NOT be eligible if:** - You have not received prior standard chemotherapy - You have active brain metastases - You have severe heart, kidney, or liver problems - You are pregnant or breastfeeding - You have uncontrolled high blood pressure or bleeding conditions Talk to your doctor to see if this trial is right for you.